F
Frederick Klauschen
Researcher at Humboldt University of Berlin
Publications - 238
Citations - 17312
Frederick Klauschen is an academic researcher from Humboldt University of Berlin. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 45, co-authored 170 publications receiving 12451 citations. Previous affiliations of Frederick Klauschen include Charité & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
On Pixel-Wise Explanations for Non-Linear Classifier Decisions by Layer-Wise Relevance Propagation.
Sebastian Bach,Alexander Binder,Grégoire Montavon,Frederick Klauschen,Klaus-Robert Müller,Wojciech Samek +5 more
TL;DR: This work proposes a general solution to the problem of understanding classification decisions by pixel-wise decomposition of nonlinear classifiers by introducing a methodology that allows to visualize the contributions of single pixels to predictions for kernel-based classifiers over Bag of Words features and for multilayered neural networks.
Journal ArticleDOI
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
Roberto Salgado,Carsten Denkert,Sandra Demaria,Nicolas Sirtaine,Frederick Klauschen,Giancarlo Pruneri,Stephan Wienert,G. Van den Eynden,Frederick L. Baehner,Frédérique Penault-Llorca,E. A. Perez,E. A. Thompson,William Fraser Symmans,Andrea L. Richardson,Jane E. Brock,Carmen Criscitiello,Helen Bailey,Michail Ignatiadis,Giuseppe Floris,Joseph A. Sparano,Zuzana Kos,Torsten O. Nielsen,David L. Rimm,Kimberly H. Allison,Jorge S. Reis-Filho,Sibylle Loibl,Christos Sotiriou,Giuseppe Viale,Sunil S. Badve,Sylvia Adams,Karen Willard-Gallo,Sherene Loi +31 more
TL;DR: Current data on the clinical validity and utility of TILs in BC are reviewed in an effort to foster better knowledge and insight in this rapidly evolving field, and to develop a standardized methodology for visual assessment on H&E sections.
Journal ArticleDOI
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert,Gunter von Minckwitz,Silvia Darb-Esfahani,Bianca Lederer,Barbara Ingold Heppner,Karsten Weber,Jan Budczies,Jens Huober,Frederick Klauschen,Jenny Furlanetto,Wolfgang D. Schmitt,Jens-Uwe Blohmer,Thomas Karn,Berit M. Pfitzner,Sherko Kümmel,Knut Engels,Andreas Schneeweiss,Arndt Hartmann,Aurelia Noske,Peter A. Fasching,Christian Jackisch,Marion van Mackelenbergh,Peter Sinn,Christian Schem,Claus Hanusch,Michael Untch,Sibylle Loibl +26 more
TL;DR: The hypothesis that breast cancer is immunogenic and might be targetable by immune-modulating therapies is supported and increased TIL concentration predicted response to neoadjuvant chemotherapy in all molecular subtypes assessed.
Journal ArticleDOI
Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization
Jan Budczies,Frederick Klauschen,Bruno Valentin Sinn,Balázs Győrffy,Wolfgang D. Schmitt,Silvia Darb-Esfahani,Carsten Denkert +6 more
TL;DR: The functionality of Cutoff Finder is illustrated by the analysis of the gene expression of estrogen receptor and progesterone receptor in breast cancer tissues, which is analyzed and correlated with immunohistologically determined ER status and distant metastasis free survival.
Journal ArticleDOI
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers
Carsten Denkert,Gunter von Minckwitz,Jan C. Brase,Bruno Valentin Sinn,Stephan Gade,Ralf Kronenwett,Berit M. Pfitzner,Christoph Salat,Sherene Loi,Sherene Loi,Wolfgang D. Schmitt,Christian Schem,Karin Fisch,Silvia Darb-Esfahani,Keyur Mehta,Christos Sotiriou,Stephan Wienert,Peter Klare,Fabrice Andre,Frederick Klauschen,Jens-Uwe Blohmer,Kristin Krappmann,Marcus Schmidt,Hans Tesch,Sherko Kümmel,Peter Sinn,Christian Jackisch,Manfred Dietel,Toralf Reimer,Michael Untch,Sibylle Loibl +30 more
TL;DR: Investigating the immunogenicity of human epidermal growth factor receptor 2 -positive and triple-negative breast cancers and immunologically relevant genes in the neoadjuvant GeparSixto trial found immunologic factors were highly significant predictors of therapy response in the trial, particularly in patients treated with Cb.